

## FORM 7

### MONTHLY PROGRESS REPORT – October 2012

**Name of CNSX Issuer:** Pivotal Therapeutics Inc. (the "Issuer").

**Trading Symbol:** PVO

**Number of Outstanding Listed Securities:** 79,453,509 common shares

**Date:** November 7, 2012

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

Over the previous month, the Issuer received four more tranches from the CDN \$5 million private placement it entered into with a U.S. Institutional Fund; Crossover Healthcare Fund LLC, an Affiliate of Summer Street Research Partners. These funds are being used for the further commercialization of its lead product VASCAZEN®. It is a prescription only medical food for the aid in the dietary management of Omega-3 deficient cardiovascular disease patients. The product is readily available through a prescription in all major pharmacies across the U.S. and is receiving reimbursement from a growing number of the nations largest private insurers. Also during the month the Company exhibited at the 2012 Cardiometabolic Health Congress in Boston, MA from Oct 10-14. This conference was the perfect place for the Company to showcase its product and educate prescribing physicians on the benefits of VASCAZEN®. Additionally, the company amended its Interim Q1 and Q2 2012 financial statements to more fully comply with International Financial Reporting Standards (IFRS).

- 2. Provide a general overview and discussion of the activities of management.**

Management is continuing to work and deliver on the objectives laid out in the business plan to commercialize VASCAZEN® and increase shareholder value. To support these efforts management has entered into a subscription agreement with Crossover Healthcare Fund LLC, an Affiliate of Summer Street Research Partners, and has received six tranches in total of the CDN \$5 million private placement. Details of the payments can be found in Form 9 on the CNSX website. The proceeds are used as working capital to build the sales of the company's lead product VASCAZEN®. Finally, to better comply with disclosure requirements under IFRS the Company filed revised Q1 and Q2 – 2012 financial statements by amending its quarterly statements of equity for both March 31, 2012 and June 30, 2012 to include comparative subtotals as at March 31, 2011 and June 30, 2011. The Company emphasized that the amended statements and MD&A disclose no change whatsoever in assets, liabilities, equity, or income from that previously filed. Copies of the revised financial statements for the first and second quarter of 2012 are available at [www.sedar.com](http://www.sedar.com) and on the CNSX website.

- 3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling,**

**exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

This item is not applicable to the Issuer for the month of October 2012.

- 4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

This item is not applicable to the Issuer for the month of October 2012.

- 5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of**

This item is not applicable to the Issuer for the month of October 2012.

- 6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

This item is not applicable to the Issuer for the month of October 2012.

- 7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

This item is not applicable to the Issuer for the month of October 2012.

- 8. Describe the acquisition of new customers or loss of customers.**

This item is not applicable to the Issuer for the month of October 2012.

- 9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.**

The name of the company's lead product VASCAZEN is now officially a

registered mark of the United States Patent and Trademark Office.

**10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

This item is not applicable to the Issuer for the month of October 2012.

**11. Report on any labour disputes and resolutions of those disputes if applicable.**

This item is not applicable to the Issuer.

**12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

This item is not applicable to the Issuer.

**13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

This item is not applicable to the Issuer.

**14. Provide details of any securities issued and options or warrants granted.**

This is not applicable to the Issuer for the month of October 2012.

**15. Provide details of any loans to or by Related Persons.**

This item is not applicable to the Issuer for the month of October 2012.

**16. Provide details of any changes in directors, officers or committee members.**

This item is not applicable to the Issues for the month of October 2012.

**17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

None.

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: November 7<sup>th</sup>, 2012

Rachelle MacSweeney  
Name of Director or Senior  
Officer

"Rachelle MacSweeney"  
Signature

President, Chief Operating  
Officer and Director  
Official Capacity

<b><i>Issuer Details</i></b> <u>Name of Issuer</u>	<u>For Month End</u> October 31, 2012	<u>Date of Report</u> (YY/MM/D) 12/11/07
<u>Issuer Address</u> 81 Zenway Blvd., Unit 10		
<u>City/Province/Postal Code</u> Woodbridge, Ontario L4H 0S5	<u>Issuer Fax No.</u> (905) 856-2177	<u>Issuer Telephone No.</u> (905) 856-9797
<u>Contact Name</u> Rachelle MacSweeney	<u>Contact Position</u> President, Chief Operating Officer & Director	<u>Contact Telephone No.</u> (905) 856-9797
<u>Contact Email Address</u> rmacsweeney@pivotaltherapeutics.us	<u>Web Site Address</u> www.pivotaltherapeutics.us	